Patient Rights in Substance Use Disorder Treatment

Federal law treats substance use disorder as a medical condition — not a moral failing, not a criminal designation — and that classification carries a specific set of legal protections that apply from the moment someone walks into a treatment facility. This page covers the rights that govern confidentiality, consent, discharge, and equal treatment for people in addiction recovery programs, including how those rights differ from general medical rights and where they carry extra force.

Definition and Scope

Substance use disorder (SUD) treatment occupies a distinct legal space because it is governed by two overlapping regulatory frameworks that most hospital visits never encounter. The first is HIPAA, which applies broadly to health information. The second — and more specific — is 42 CFR Part 2, a federal regulation administered by the Substance Abuse and Mental Health Services Administration (SAMHSA) that applies exclusively to records from federally assisted SUD treatment programs.

42 CFR Part 2 is significantly stricter than HIPAA on disclosure. Under this regulation, a SUD treatment program cannot acknowledge that a patient is even enrolled without that patient's written consent — a level of protection that standard medical records do not carry. This distinction matters because SUD-related information disclosed without consent has historically been used in employment decisions, custody proceedings, and criminal cases. The federal rule is designed specifically to prevent those consequences.

The scope of protected facilities includes outpatient clinics, residential treatment centers, detox units, and methadone maintenance programs that receive any federal funding — which covers the vast majority of licensed treatment providers in the United States. Behavioral health facility rights extend these protections further within institutional settings.

How It Works

A patient entering SUD treatment holds several enforceable rights from day one:

1. Confidentiality beyond HIPAA: Records cannot be disclosed to law enforcement, employers, or family members without a signed consent form that specifies the recipient, the purpose, and an expiration date. A general medical release form is not sufficient under 42 CFR Part 2.
2. Informed consent before treatment: No medication-assisted treatment (MAT) — including buprenorphine, methadone, or naltrexone — can be administered without explanation of its risks, benefits, and alternatives. This right is protected under informed consent law and cannot be waived by facility policy.
3. The right to refuse treatment: A patient may decline specific treatments, including MAT, even if clinical staff recommend them. The right to refuse treatment applies in SUD settings just as it does in general medicine.
4. Non-discrimination protections: Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Act (ADA) classify SUD as a disability in most contexts, meaning treatment facilities cannot deny services based on addiction status alone.
5. Protection from involuntary discharge: Facilities operating under SAMHSA guidelines must follow a defined process before discharging a patient involuntarily, including clinical review and reasonable notice.

SAMHSA's 2020 revision to 42 CFR Part 2 brought it closer to HIPAA in certain respects — for instance, allowing disclosures for treatment, payment, and healthcare operations with a single broad consent rather than per-disclosure authorization — while still maintaining its core prohibition on non-consensual disclosure to non-healthcare entities.

Common Scenarios

Scenario A: The family member who wants records. A parent calls a treatment center asking about their adult child's enrollment status. Under 42 CFR Part 2, staff cannot confirm or deny the patient is there, regardless of the parent's relationship. The adult patient must provide written, specific consent before any information is shared.

Scenario B: A criminal court requests treatment records. Without a court order that meets the specific requirements of 42 CFR Part 2 — which are distinct from ordinary subpoena standards — a SUD treatment program cannot comply with a law enforcement or prosecutor request. Patients can consult the grievance and appeals process if they believe a facility has improperly disclosed records.

Scenario C: Insurance denies coverage for residential treatment. The Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 requires that insurers cover SUD treatment at parity with medical and surgical benefits. A denial that applies stricter criteria to a 28-day residential stay than to a comparable medical admission may constitute a parity violation. Patient rights and insurance denials covers the appeals framework in detail.

Scenario D: Discharge during active crisis. A patient who is physically dependent on opioids cannot be safely discharged without a stabilization plan. Involuntary or abrupt discharge in these circumstances may implicate emergency medical treatment rights under EMTALA if the facility has an emergency department.

Decision Boundaries

Not all SUD-related protections apply in all settings. The distinction between what 42 CFR Part 2 covers and what it does not is consequential.

The regulation applies to federally assisted programs — meaning programs that receive federal funds, are licensed under a federal program, or are authorized by the DEA to dispense controlled substances in a treatment context. A private-pay, unlicensed wellness retreat that markets "addiction recovery" services almost certainly falls outside Part 2's scope. In that setting, only HIPAA and applicable state patient rights laws apply.

For patients in Medicaid-funded SUD treatment, an additional layer of protections applies through Medicaid managed care rules, which require grievance procedures and continuity of care standards (Medicaid patient rights addresses these specifically).

The ADA's disability classification for SUD has one major carve-out: it does not protect individuals currently engaging in illegal drug use. A person who completed a treatment program and is in recovery retains ADA protections; a person who is actively using illegal substances at the time of a facility interaction does not. This boundary is defined by the statute itself — 42 U.S.C. § 12114 — and has been interpreted consistently across federal circuit courts.

Understanding where one protection ends and another begins is not an academic exercise. For someone navigating a patient rights complaint, knowing which law applies — and to which type of facility — determines which agency has jurisdiction and which remedies are available.